Nektar Therapeutics (NKTR) Stock Price, Quote & News

Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 482 5300

Fax: 415 339 5300

Website: www.nektar.com

Address:

455 Mission Bay Boulevard South, San Francisco, United States

OMNIFALL Aug. 18 at 7:11 PM

$NKTR i have a dream. no settlement. trial. stock falls to the 50s. but wait.. $1,000,000 awarded by jury. stock shoots to the low 90s. people are still afraid. Q4 shows complete flatline after 24w off drug. rezpeg appears to be a true cure stock breaks 180 on the news people are still waiting for 52w off-drug ad data... it arrives same story rezpeg is a cure acquired for 30-40b. fails in ph3 because it fucking causes cancer

1 · Reply

BK217 Aug. 18 at 3:06 PM

$NKTR I think September is going to be a disaster month for this stock. Selling covered calls…

4 · Reply

ShibWillow Aug. 17 at 8:54 PM

Looks like Volume is shifting to MLEC now 🚀 MLEC has 573k shares remaining to public Look at what WETO / IPST did on similar share numbers today. MLEC getting squeezed now - Added a big position for a parabolic run! $VWAV $NKTR $ARTV $BTQ mww

0 · Reply

george4it Aug. 17 at 2:28 PM

$NKTR Another 500 shares added to my stack, bought between 70.80 and 72.80.

0 · Reply

PercyFinn Aug. 17 at 1:48 PM

$NKTR The action (and reaction) will happen before Sept. 8.

0 · Reply

jerrybe5000 Aug. 15 at 3:15 PM

$NKTR nobody talked about earnings call. Anything?

0 · Reply

george4it Aug. 15 at 12:32 PM

$NKTR Ready to add again if it dips below 70.

0 · Reply

twit0913 Aug. 15 at 10:46 AM

$NKTR in theory, a big pharma company with very deep pockets and extensive trading connections, would have a vested interest in driving down the value of this company before a settlement or an offer....if it's an offer, they could help cover any short position their proxies may have incurred

0 · Reply

beckinvestllc Aug. 14 at 9:17 PM

$NKTR just tried to post about the price action dropping to touch the 20 day SMA, but my post went into a black hole apparently.

0 · Reply

StocktwitsNews Aug. 14 at 12:12 PM

NKTR Q2 2026 Earnings Summary $NKTR https://stocktwits.com/news/earnings/ai summaries/nktr-q2-2026-earnings-summary/cZotKfCRJ0T

0 · Reply

Nektar Therapeutics Earnings Call Transcript: Q2 2026

Aug 13, 2026, 5:00 PM EDT - 5 days ago

Nektar Therapeutics Earnings release: Q2 2026

Aug 13, 2026, 5:00 PM EDT - 5 days ago

Nektar Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 4:15 PM EDT - 5 days ago

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

Jul 28, 2026, 6:00 PM EDT - 21 days ago

Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets

Jul 24, 2026, 4:15 PM EDT - 25 days ago

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 21, 2026, 7:00 AM EDT - 4 weeks ago

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Jun 4, 2026, 5:00 PM EDT - 2 months ago

Nektar Therapeutics Transcript: AGM 2026

Jun 3, 2026, 1:20 PM EDT - 2 months ago

Nektar Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 6:15 PM EDT - 2 months ago

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York

May 7, 2026, 5:00 PM EDT - 3 months ago

Nektar Therapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 5:00 PM EDT - 3 months ago

Nektar Therapeutics Earnings release: Q1 2026

May 7, 2026, 5:00 PM EDT - 3 months ago

Nektar Therapeutics Quarterly report: Q1 2026

May 7, 2026, 4:15 PM EDT - 3 months ago

Nektar Therapeutics Reports First Quarter 2026 Financial Results

Apr 28, 2026, 6:00 PM EDT - 4 months ago

Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Nektar Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Nektar Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 4:15 PM EDT - 4 months ago

Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Apr 21, 2026, 9:30 PM EDT - 4 months ago

Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering

Apr 20, 2026, 4:01 PM EDT - 4 months ago

Nektar Therapeutics Announces Proposed Public Offering

Apr 20, 2026, 11:43 AM EDT - 4 months ago

This Biotech Stock Soars on Hair Loss Trial Results. It's Not a Cure for Baldness.

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Nektar Therapeutics Transcript: Study update

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Nektar Therapeutics Press release: Study update

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Nektar Therapeutics Slides: Study update

Apr 20, 2026, 7:30 AM EDT - 4 months ago

52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin

Apr 19, 2026, 12:00 PM EDT - 4 months ago

Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026

Apr 9, 2026, 8:23 AM EDT - 4 months ago

NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline

Mar 31, 2026, 2:50 PM EDT - 5 months ago

NKTR Stockholders Have Rights – If You Lost Money Investing in Nektar Therapeutics Contact Robbins LLP for Information About Recovering Your Losses

Mar 28, 2026, 12:36 PM EDT - 5 months ago

Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting

Mar 20, 2026, 10:00 AM EDT - 5 months ago

Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting

Mar 12, 2026, 5:00 PM EDT - 5 months ago

Nektar Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 5:00 PM EDT - 5 months ago

Nektar Therapeutics Annual report: Q4 2025

Mar 12, 2026, 5:00 PM EDT - 5 months ago

Nektar Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 4:15 PM EDT - 5 months ago

Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 10, 2026, 5:58 PM EDT - 5 months ago

NEKTAR THERAPEUTICS (NKTR) INVESTOR ALERT Investors With Large Losses in Nektar Therapeutics Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Mar 9, 2026, 7:10 AM EDT - 5 months ago

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Nektar Therapeutics, (NKTR)

Mar 4, 2026, 9:10 AM EST - 5 months ago

Nektar Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 6:00 PM EST - 6 months ago

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

Feb 24, 2026, 6:00 PM EST - 6 months ago

Nektar Therapeutics to Participate in Two Investor Conferences in March

Feb 17, 2026, 7:00 AM EST - 6 months ago

Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis

Feb 13, 2026, 4:15 PM EST - 6 months ago

Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 13, 2026, 9:30 AM EST - 6 months ago

Can NKTR Stock Sustain Its 1,000% Rally?

Feb 11, 2026, 10:23 PM EST - 6 months ago

Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering

Feb 10, 2026, 8:00 AM EST - 6 months ago

Nektar Therapeutics Transcript: Study result

Feb 10, 2026, 8:00 AM EST - 6 months ago

Nektar Therapeutics Press release: Study result

Feb 10, 2026, 8:00 AM EST - 6 months ago

Nektar Therapeutics Slides: Study result

Feb 10, 2026, 7:00 AM EST - 6 months ago

New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing

Feb 9, 2026, 4:15 PM EST - 6 months ago

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

Jan 15, 2026, 6:58 PM EST - 7 months ago

Nektar.io Introduces DIRT: Materials Management for the Construction Industry

Dec 16, 2025, 8:00 AM EST - 8 months ago

Nektar Therapeutics Transcript: Study Result

Dec 16, 2025, 8:00 AM EST - 8 months ago

Nektar Therapeutics Press release: Study Result

Dec 16, 2025, 8:00 AM EST - 8 months ago

Nektar Therapeutics Slides: Study Result

Dec 15, 2025, 6:00 PM EST - 8 months ago

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

Nov 20, 2025, 6:00 AM EST - 9 months ago

Nektar Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 8, 2025, 5:45 PM EST - 10 months ago

New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Nov 6, 2025, 5:00 PM EST - 10 months ago

Nektar Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

Nektar Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

Nektar Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 4:15 PM EST - 10 months ago

Nektar Therapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 6:00 PM EDT - 10 months ago

Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Oct 28, 2025, 6:00 PM EDT - 10 months ago

Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

Oct 28, 2025, 12:36 PM EDT - 10 months ago

San Francisco is making a comeback. So are these stocks from the City by the Bay

MAZE REAL

Oct 22, 2025, 8:00 AM EDT - 10 months ago

Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Sep 18, 2025, 8:45 AM EDT - 11 months ago

Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025

Sep 15, 2025, 2:30 PM EDT - 1 year ago

Nektar Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 10, 2025, 10:30 AM EDT - 1 year ago

Nektar Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 7:00 AM EDT - 1 year ago

Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025

Sep 3, 2025, 7:00 PM EDT - 1 year ago

Nektar Therapeutics to Participate in Two Investor Conferences in September

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Nektar Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Nektar Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

Nektar Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:15 PM EDT - 1 year ago

Nektar Therapeutics Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 6:00 PM EDT - 1 year ago

Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

Jul 29, 2025, 9:00 AM EDT - 1 year ago

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata

Jul 2, 2025, 4:15 PM EDT - 1 year ago

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

OMNIFALL Aug. 18 at 7:11 PM

1 · Reply

BK217 Aug. 18 at 3:06 PM

$NKTR I think September is going to be a disaster month for this stock. Selling covered calls…

4 · Reply

ShibWillow Aug. 17 at 8:54 PM

0 · Reply

george4it Aug. 17 at 2:28 PM

$NKTR Another 500 shares added to my stack, bought between 70.80 and 72.80.

0 · Reply

PercyFinn Aug. 17 at 1:48 PM

$NKTR The action (and reaction) will happen before Sept. 8.

0 · Reply

jerrybe5000 Aug. 15 at 3:15 PM

$NKTR nobody talked about earnings call. Anything?

0 · Reply

george4it Aug. 15 at 12:32 PM

$NKTR Ready to add again if it dips below 70.

0 · Reply

twit0913 Aug. 15 at 10:46 AM

0 · Reply

beckinvestllc Aug. 14 at 9:17 PM

$NKTR just tried to post about the price action dropping to touch the 20 day SMA, but my post went into a black hole apparently.

0 · Reply

StocktwitsNews Aug. 14 at 12:12 PM

NKTR Q2 2026 Earnings Summary $NKTR https://stocktwits.com/news/earnings/ai summaries/nktr-q2-2026-earnings-summary/cZotKfCRJ0T

0 · Reply

StocktwitsEarnings Aug. 14 at 11:22 AM

$NKTR Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.23 up 58.31% YoY • Reported revenue of $10.13M down -9.34% YoY

0 · Reply

jerrybe5000 Aug. 13 at 9:43 PM

$NKTR I missed the first 25 minutes. But the Q&A I am listening to for the last 20 minutes is really solid. They are very transparent. Mary is impressive.

0 · Reply

Merlintrader Aug. 13 at 9:10 PM

Nektar Therapeutics (Nasdaq: $NKTR) Stock Hub: Rezpegaldesleukin Enters Phase 3, but the Market Must Separate AD Strength from AA Uncertainty https://www.merlintrader.com/nektar-therapeutics-stock-hub/

0 · Reply

stocknrolex Aug. 13 at 8:23 PM

$NKTR anyone home?

0 · Reply

flyboiyoungkid Aug. 13 at 8:21 PM

$NKTR 40% beat let’s ride boys

1 · Reply

flyboiyoungkid Aug. 13 at 8:18 PM

$NKTR let’s ride that thing

0 · Reply

deedeethegenius Aug. 13 at 8:17 PM

$STNE $NKTR $BRUN $NMAX $DLO

0 · Reply

Estimize Aug. 13 at 3:01 PM

$NKTR reports after the close, Estimize Consensus +0.13 EPS and +0.73M Revs compared to WS http://www.estimize.com/nktr/fq2-2026?utm_conten

0 · Reply

BK217 Aug. 12 at 1:02 PM

$NKTR good bit of short covering at last report

0 · Reply

george4it Aug. 11 at 5:28 PM

$NKTR

0 · Reply

AdamURAtoFookingNeptune Aug. 10 at 6:17 PM

$INCY $ABCL $NKTR $UTHR $EXEL when I’m not being beartard and pissed sometimes be sweet w it

0 · Reply

EquityVoyager_1 Aug. 10 at 1:50 PM

BULLISH OPTIONS FLOW IS STARTING TO LIGHT UP Big call-side activity caught my attention this morning: $RGTI → 35C | 11/20 | $600K | Avg $0.80 $CVX → 200C | 8/14 | $273K | Avg $0.18 $ONDS → 9.5C | 8/28 | $500K | Avg $0.79 $NKTR → 100C | 9/18 | $700K | Avg $1.80 $FRO → 60C | 11/20 | $266K | Avg $0.67 Unusual bullish flow is worth watching - especially when volume starts accelerating. If you would like to learn more about marketing strategies, please visit my personal webpage.

0 · Reply

Market Cap	2.46B
Revenue (ttm)	55.23M
Net Income (ttm)	-164.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-297.08%
Debt to Equity Ratio	0.00

Volume	565,500
Avg Vol	935,850
Day's Range	N/A - N/A
Shares Out	33.79M
Stochastic %K	47%
Beta	1.14
Analysts	Strong Sell
Price Target	$145.90